Tokyo, May 14 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061557) titled 'Nationwide survey on hemophagocytic syndrome as an immune-related adverse event in the treatment of malignant thoracic tumors' on May 13.
Study Type:
Observational
Primary Sponsor:
Institute - Nihon University
Condition:
Condition - Malignant thoracic tumor
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To clarify the clinical characteristics of cases of hemophagocytic syndrome caused by immune checkpoint inhibitors in patients with malignant thoracic tumors.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
= 265 mg/dL or Fibrinogen = 500 ng/mL
8 Soluble IL-2 receptor >= 2,400 U/mL
3)Other causes of hemophagocytic syndrome have been excluded.
Key exclusion criteria - 1)Cases in which the subject is found not to meet the eligibility criteria after enrollment in this study
2)Individuals who have submitted a request to withdraw from participation in this study
Target Size - 50
Recruitment Status:
Recruitment status - No longer recruiting
Date of protocol fixation - 2024 Year 12 Month 20 Day
Date of IRB - 2025 Year 03 Month 21 Day
Anticipated trial start date - 2025 Year 03 Month 21 Day
Last follow-up date - 2026 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070423
Disclaimer: Curated by HT Syndication.
